Clínica Baviera CBAV.MC
SpainHealthcare · Diagnostics & ResearchBolsa de Madrid (BME) · EUR
0.00 EUR (−100.0%)
Trading 2120.00 €Open account ↗
XTB0.00 €affiliateOpen account ↗
eToro0.86 €Open account ↗XTB0.00 €★ featured · affiliateOpen account ↗Trading 2120.00 €Open account ↗eToro0.86 €Open account ↗XTB0.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Clínica Baviera is a Spanish company specialized in ophthalmology, operating a network of eye surgery clinics and vision treatments, with a business model based on providing high-quality private medical services.
Listed on Bolsa de Madrid (BME) · Symbol CBAV.MC · BME: CBAV · Currency EUR
Key points
from its scores- ✓Good share-price trend8.6
- ✓High-quality business8.4
- ✓Strong growth8.0
- !Somewhat demanding valuation5.2
AI analysis
bottom line, main risk, context and newsQuality and growth justify the premium, although the forward P/E of 31.70 suggests demanding expectations.
Clínica Baviera presents very solid fundamentals: ROE of 45.93%, ROIC of 37.87%, and earnings growth of 38.70%, with a healthy balance sheet (Net Debt/EBITDA of 0.22). Its valuation is reasonable (P/E 19.44) and the dividend is sustainable, making it an attractive option in the healthcare sector.
The main risk is geographic concentration in Spain, with elevated governance risk, which could affect healthcare regulation or minority shareholder protection.
Context and risks
Clínica Baviera operates in Spain, a country with elevated governance risk according to the assigned profile, which may affect regulatory stability and minority shareholder protection. However, its private healthcare business is less sensitive to politics than other sectors, and its low leverage (Net Debt/EBITDA of 0.22) limits the impact of interest rates.
Is Clínica Baviera stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 27% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 19.4 | 26.7 | −27% |
| EV / EBITDA | 10.5 | 14.5 | −28% |
| Price / book | 8.0 | 4.1 | +95% |
| Price / sales | 2.8 | 3.4 | −18% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.2 out of 10 (median for Healthcare: 4.7).
Average analyst target: 0.00 EUR, −100.0% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 7.1 (sector 6.5), Growth 8.0 (sector 6.6).
Classic formulas with standard assumptions (0.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 19.4
- Forward P/E
- 31.7
- EV / EBITDA
- 10.5
- Price / book
- 8.0
- Price / sales
- 2.8
- PEG
- 2.70
- Market cap
- 894.6M EUR
- Enterprise value
- 928.8M EUR
Profitability
- ROE
- 45.9%
- ROA
- 16.9%
- ROIC (approx.)
- 37.9%
- Gross margin
- 49.8%
- Operating margin
- 21.6%
- Net margin
- 14.3%
- Free cash flow
- 42.4M EUR
- FCF yield
- 4.7%
- Cash conversion
- 48%
Solvency
- Total debt
- 71.4M EUR
- Net debt
- 19.8M EUR
- Cash
- 51.6M EUR
- EBITDA
- 88.8M EUR
- Net debt / EBITDA
- 0.22
- Debt / equity
- 63.65
- Current ratio
- 0.94
- Quick ratio
- 0.86
Growth
- Revenue growth
- +13.3%
- Earnings growth
- +38.7%
- EPS (TTM)
- 2.87 EUR
- EPS (forward)
- 1.76 EUR
Dividend
- Dividend yield
- 2.8%
- Payout
- 54.7%
Risk and market
- Beta
- 0.75
- Analyst consensus
- none (0)
- Target price
- 0.00 EUR
- 52-week range
- 40.10 – 62.00
Recent news
All CBAV.MC news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Clínica Baviera
Is Clínica Baviera stock cheap or expensive?
On P/E and EV / EBITDA, it trades 27% below the Healthcare median on average. Valuation score: 5.2 out of 10 (median for Healthcare: 4.7). Average analyst target: 0.00 EUR, −100.0% versus the price. This is not investment advice.
What score does Clínica Baviera get on MeridIAn Screener?
It scores 7.1 out of 10, rank 157 of 2,130 (better than 91% of the companies analysed). Its strongest category is Momentum (8.6) and its weakest, Valuation (5.2). Analysis of 08/10/2026.
What is Clínica Baviera's P/E ratio?
Its P/E is 19.4: the share price equals 19.4 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 31.7.
How much is Clínica Baviera worth on the stock market?
Its market capitalisation is 894.6M EUR and its enterprise value, debt included, is 928.8M EUR.
How much debt does Clínica Baviera have?
Its net debt (debt minus cash) is 19.8M EUR. That is 0.22 times its EBITDA; the Healthcare median is 1.53.
Does Clínica Baviera pay a dividend?
Yes: its dividend yield is 2.81% and it pays out 55% of its earnings.
How has Clínica Baviera stock performed over the last year?
It has risen 39.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 40.10 and 62.00 EUR. Past performance does not guarantee future results.